… Platinum-based chemotherapy plus cetuximab in head and neck cancer. … versus cetuximab
with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck …

… Cetuximab remains to date the only targeted therapy approved for the treatment of head and
neck squamous cell carcinoma (… have been tested in HNSCC, cetuximab, an IgG1 subclass …

… Objective: In patients with head and neck squamous cell carcinoma (HNSCC), cetuximab
[a … While biomarkers of resistance to cetuximab have been identified in metastatic colorectal …

… Currently, cetuximab associated with radiotherapy is limited to the … cetuximab efficacy in
this cancer setting are still lacking. This review focuses on the mechanisms of action of cetuximab…

… Here, we assessed outcomes with nivolumab, by prior cetuximab exposure, in patients with
recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) who …

… new cases of head and neck cancers worldwide, with … percent of head and neck cancers are
squamous cell carcinoma (… {5-FU}] plus cetuximab followed by cetuximab maintenance until …

… Pembrolizumab (PD-1 inhibitor) and cetuximab (EGFR … or metastatic head and neck squamous
cell carcinoma (HNSCC). … or metastatic squamous cell carcinoma of the head and neck …

… sequence of cetuximab and ICI in R/M HNSCC may affect clinical outcomes. Cetuximab
prior to ICI was associated with worse outcomes while the efficacy of cetuximab may be …

… squamous cell cancer of the head and neck (SCCHN) have a poor prognosis and few efficacious
treatment options. Cetuximab … a synergistic effect of taxanes and cetuximab [4], which in …

… Concurrent cisplatin with radiotherapy (CRT) or concurrent cetuximab with radiotherapy (BRT)
improves outcomes in locally advanced head and neck squamous cell carcinoma (…